ClinicalTrials.gg
Active, not recruitingNCT04279847LIMBERUpdated Apr 1, 2026

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

A Phase 1 interventional study of INCB057643 and Ruxolitinib in Myelofibrosis, Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, sponsored by Incyte Corporation. Active, not recruiting at 48 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Myelofibrosis by Incyte Corporation — 3 open to participants now, 6 under way, none of them phase 3. Primary Myelofibrosis · Incyte Corporation.

Enrollment
8th of 22
140 · median 107
Started
2021
with 4 others
Phase 1
7 of 23
3 open now
Registered
14th of 23
by date

Among the 23 studies in Primary Myelofibrosis by Incyte Corporation, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2021, is one of 7 in phase 1, and was the 14th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 23 studies in Primary Myelofibrosis by Incyte Corporation are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Myelofibrosis by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.

03

Conditions studied

  • Myelofibrosis
  • Myelodysplastic Syndrome
  • Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
  • Myeloproliferative Neoplasm
  • Relapsed or Refractory Primary Myelofibrosis
  • Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
  • ET (Essential Thrombocythemia)

Keywords

  • Myelofibrosis
  • myelodysplastic syndrome
  • myelodysplastic/myeloproliferative neoplasm overlap syndrome
  • myeloproliferative neoplasm
  • BET protein inhibitor
  • relapsed primary myelofibrosis
  • refractory primary myelofibrosis
  • secondary myelofibrosis
  • post-polycythemia vera myelofibrosis
  • post-essential thrombocythemia myelofibrosis
  • LIMBER
  • ET (essential thrombocythemia)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older at the time of signing the .
  • Part 1 Monotherapy: Participants with confirmed diagnosis of MF (primary, or post-PV and post-ET), MDS, MDS/MPN, or ET who have received at least 1 ; are either refractory, relapsed, or intolerant to the last therapy; and there is no available therapy that would provide clinical benefit in the opinion of the investigator.

    • a. MF with (palpable spleen and symptoms) as defined in the protocol and risk category of intermediate 2 or high according to DIPSS. MF participants must have received a JAK inhibitor(s), such as ruxolitinib.
    • b. ET participants should have disease refractory to hydroxyurea as defined by the protocol.
  • Part 2 Combination with ruxolitinib.

    • a. Primary MF or secondary MFs (post-PV MF and post-ET MF), or cytologically confirmed, with measurable disease (palpable spleen and symptoms) as defined in the protocol, either currently receiving ruxolitinib with suboptimal response or JAKi-naive.
    • b. Suboptimal response is defined as currently being treated with ruxolitinib monotherapy at a stable dose for ≥ 8 weeks immediately preceding the first dose of study treatment. One dose reduction due to toxicities within 8 weeks prior to Study Day 1 is permitted.
    • c. JAKi-naive is defined as those participants that have no prior use of any JAK inhibitor, including ruxolitinib, and;
    • d. Part 2 dose escalation: Risk category of intermediate-2 or high according to DIPSS.
    • e. Part 2 dose expansion: Risk category of intermediate-1, intermediate-2, or high according to DIPSS.
    • f. Part 2 dose expansion participants with chronic MF are defined as participants with bone marrow myeloblast percentage \< 5% (not applicable if dry tap or blast count deemed not reliable by the investigator) and blast count in peripheral blood \< 1% at screening and who are currently receiving ruxolitinib and having a suboptimal response.

Note: Study treatment should be delayed if peripheral blood blast count at baseline is > 3%; treatment should only be started with medical monitor approval.

  • g. Part 2 dose expansion participants with accelerated-phase MF are defined as having either a bone marrow myeloblast percentage ≥ 5% to \< 20% or a myeloblast percentage ≥ 10% in peripheral blood on 2 occasions at least 2 weeks apart, AND are currently receiving ruxolitinib and have a suboptimal response.
  • h. Part 2 dose expansion participants with JAKi-naive MF are eligible to receive ruxolitinib, with peripheral blood blast count of \< 10% at the screening hematology assessment.

    • Must not be a candidate for potentially curative therapy, including hematopoietic stem cell transplantation.
    • performance status 0 to 2.
    • ≥ 24 weeks.
    • Willingness to avoid pregnancy or fathering children based on criteria.
  • a. Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study treatment and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.
  • b. Women of must have a negative serum pregnancy test at screening and before the first dose on Day 1 and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.
  • c. Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea without any other medical reasons such as treatment with anticancer agents) are eligible.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a BET inhibitor.
  • Receipt of anticancer medications or drugs within the protocol-defined interval before the first dose of study treatment. For Part 2 JAKi-naive, prior use of a JAK inhibitor (including ruxolitinib) and no use of experimental drug therapy for MF or any other standard drug (except hydroxyurea) used for MF or another indication within 3 months of starting study drug. For participants with suboptimal response to ruxolitinib, ruxolitinib will continue at the participants' current ongoing doses, no ruxolitinib is needed.
  • Participants with exclusionary laboratory values at screening defined as, including, but not limited to,

    • a. . Part 1 (monotherapy dose expansion, MF): \< 75 × 109/L. Part 1 (monotherapy dose expansion, ET): \< 450 × 109/L. Part 2 (combination dose escalation and expansion): \< 75 × 109/L. Part 2 (combination dose expansion, JAKi-naïve MF): \< 100 × 109/L.
    • b. : Participants unwilling to receive red blood cell transfusion to treat low hemoglobin levels are excluded.
    • c. ANC \< 0.75 × 109/L.
  • inadequate renal, hepatic and coagulation functions as defined in the protocol.
  • Concurrent anticancer therapy other than the therapies being tested in this study.
  • Participants who have received hematopoietic stem cell transplantation within 6 months of enrollment (unless approved by the medical monitor), or have active , or have received therapy following allogeneic transplant within 2 weeks of the first dose of study treatment.
  • Unless approved by the medical monitor, may not have received autologous hematopoietic stem-cell transplant within 3 months before the first dose of study treatment.
  • Significant concurrent, uncontrolled medical condition, including but not limited to, significant GI disorder, history of or current or uncontrolled cardiac disease, history or presence of an abnormal that, in the investigator's opinion, is clinically meaningful, and history of bleeding disorder or at a high risk of bleeding.
  • Active bacterial, fungal, parasitic, or viral infection that requires therapy.
  • Current use of prohibited medication as described in the protocol, including the use of any potent inhibitors or inducers within 14 days or 5 half lives (whichever is longer) before the first dose of study treatment.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Part 1 : INCB057643 Monotherapy

    INCB057643 dose escalation and dose expansion

    Drug: INCB057643

  • Experimental
    Part 2 : INCB057643 Combination with Ruxolitinib

    Combination arm in dose escalation and dose expansion

    Drug: INCB057643 · Drug: Ruxolitinib

Interventions

  • INCB057643 dose escalation and dose expansion.

  • Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with ruxolitinib.

    Time frame: Up to approximately 9 months

Secondary outcomes

  1. Spleen Volume Response

    Defined as achieving a protocol defined reduction at Week 24 relative to baseline as measured by MRI or CT scan.

    Time frame: Week 24

  2. Duration of a Spleen Volume Response from baseline (MF only)

    Defined as the interval between the first spleen volume response and the date of the first measurement that no longer achieves the protocol defined criteria.

    Time frame: Up to approximately 9 months

  3. Symptom Response Rate (MF or ET)

    Defined as the proportion of participants who achieve a protocol defined reduction in Total Symptomatic Score (TSS) relative to baseline as measured by the MPN-symptom assessment form (SAF) TSS.

    Time frame: Week 24

  4. Anemia Response (MF only)

    A hemoglobin increase of 1.5 g/dL relative to baseline for any "rolling" 12-week period during the study treatment period, if transfusion independent (TI) at baseline or Achieving TI for any "rolling" 12-week period during the study treatment period, if transfusion dependent (TD) at baseline.

    Time frame: Up to approximately 9 months

  5. Duration of Anemia Response (MF only)

    The interval from the first onset of anemia response to the earliest date of loss of anemia response that persists for at least 4 weeks or death from any cause for the TI participants at baseline or duration of RBC-TI period for participants achieving RBC-TI for at least 12 consecutive weeks during the study treatment period for the TD participants at baseline.

    Time frame: Up to approximately 9 months

  6. Changes in hemoglobin value from baseline (MF only)

    Defined as the mean change from baseline in the hemoglobin value over 12-week treatment periods.

    Time frame: Up to approximately 9 months

  7. Red Blood Cell (RBC) Transfusion Burden (MF only)

    Defined as the average number of RBC units per participant-month through Weeks 12, 24, and 48.

    Time frame: Up to approximately 9 months

  8. Overall response (ET only)

    Defined as proportion of participants with complete response or partial response and hematological improvement/response as per definition for ET.

    Time frame: Up to approximately 9 months

  9. Duration of platelet count reduction or White Blood Cell (WBC) count reduction (ET only)

    Defined as platelet count reduction or WBC count reduction lasting ≥ 12 weeks.

    Time frame: Up to approximately 9 months

  10. Bone Marrow (BM) Blast Complete Remission (MF, myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MPN))

    Defined as BM blasts achieving the protocol defined criteria.

    Time frame: Up to approximately 9 months

  11. BM Blast Partial Remission (MF, MDS, and MDS/MPN)

    Defined as BM blasts achieving the protocol defined criteria.

    Time frame: Up to approximately 9 months

  12. Peripheral Blast Complete Remission (MF, MDS, and MDS/MPN)

    Defined as peripheral blasts achieving the protocol defined criteria.

    Time frame: Up to approximately 9 months

  13. Peripheral Blast Partial Remission (MF, MDS, and MDS/MPN)

    Defined as peripheral blast achieving the protocol defined criteria.

    Time frame: Up to approximately 9 months

  14. Durable Blast Complete or Partial remission (MF, MDS, and MDS/MPN)

    Defined as achieving the protocol defined criteria.

    Time frame: Up to approximately 9 months

07

Study locations

48 sites
08

References and documents

Individual participant data

Plan to share: No — Access to patient level data is not available for this study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Apr 2027, 74 months after the start.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Feb 21, 2020
StartActual
Feb 23, 2021
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04279847
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 21, 2020
Start date
Feb 23, 2021
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Apr 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INCB057643

Start the discussion